Venous Therapies

This channel includes news and new technology innovations of Venous Therapies including deep vein thrombosis (DVT) and vena cava filters.

An IVC filter seen under X-ray, left. Right, two sizes of the Philips excimer laser technology currently on the U.S. market for EP lead extraction. The CO2 laser technology is able to gently ablate scar tissue encasing leads to enable their extraction. 

News | Inferior Vena Cava Filters | July 27, 2021
July 27, 2021 — The U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD) to a...
Leveraging Vivasure Medical’s PerQseal vascular closure device technology, PerQseal Blue consists of an intravascular patch designed to seal the vessel from the inside, returning the vein to its natural state after it dissolves over time, so no foreign bodies are left behind.

Leveraging Vivasure Medical’s PerQseal vascular closure device technology, PerQseal Blue consists of an intravascular patch designed to seal the vessel from the inside, returning the vein to its natural state after it dissolves over time, so no foreign bodies are left behind.
 

News | Vascular Closure Devices | July 15, 2021
July 15, 2021 — Vivasure Medical announced its development program for PerQseal Blue, a sutureless and fully...
FDA Clears Pradaxa as First Oral Anticoagulant for Children. Dabigatran, has been cleared by the FDA
News | Antiplatelet and Anticoagulation Therapies | June 21, 2021
June 21, 2021 — The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's dabigatran etexilate (...
The Bluegrass Vascular Surfacer System is designed to reliably, efficiently and repeatedly gain central venous access by inserting the Surfacer System through the right femoral vein and navigating it up through the patient’s venous system with an exit point in the right internal jugular vein, the optimal location for placing a central venous catheter. 

The Surfacer System is designed to reliably, efficiently and repeatedly gain central venous access by inserting the Surfacer System through the right femoral vein and navigating it up through the patient’s venous system with an exit point in the right internal jugular vein, the optimal location for placing a central venous catheter. 

News | EP Lab | May 06, 2021
May 6, 2021 - Bluegrass Vascular Technologies announced the publication of a report documenting the clinical utility of...
Videos | Coronavirus (COVID-19) | April 01, 2021
Behnood Bikdeli M.D., a cardiologist at the Brigham and Women’s Hospital, Harvard Medical School, Boston, offers an...
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can potentiate all 3 sides of Virchow’s Triad of coagulopathy, including endothelial dysfunction, blood flow stasis, and hypercoagulability. Angiotensin-converting enzyme-2 (ACE-2)–dependent viral entry and the virus-induced inflammatory response can lead to endothelial dysfunction. Clotting Prevention in COVID-19 Patients, Thrombosis Prevention in COVID-19 Patients, Preventing blood clots in COVID-19 patients

Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can potentiate all 3 sides of Virchow’s Triad of coagulopathy, including endothelial dysfunction, blood flow stasis and hypercoagulability. Angiotensin-converting enzyme-2 (ACE-2)–dependent viral entry and the virus-induced inflammatory response can lead to endothelial dysfunction. Additional figure included in the JACC article.

Feature | Antiplatelet and Anticoagulation Therapies | March 22, 2021 | By Dave Fornell, Editor
A comprehensive review or more than 80 randomized controlled trials (RCTs) investigating how to best manage optimal...
FDA Clears Zilver Vena Venous Self-Expanding Stent
News | Venous Therapies | February 22, 2021
February 22, 2021 — The U.S. Food and Drug Administration (FDA) recently cleared the Cook Medical Zilver Vena Venous...
The FDA has granted 510(k) clearance for the Inari Medical Inc. FlowTriever system for the treatment of clot in transit (CIT) in the right atrium. FlowTriever is the first thrombectomy system not requiring a cardiopulmonary bypass circuit to be FDA cleared for blood clots in the right atrium. 

The FDA has granted 510(k) clearance for the Inari Medical Inc. FlowTriever system for the treatment of clot in transit (CIT) in the right atrium. FlowTriever is the first thrombectomy system not requiring a cardiopulmonary bypass circuit to be FDA cleared for blood clots in the right atrium. 

News | Thrombectomy Devices | January 08, 2021
January 8, 2021 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Inari Medical Inc....
Thrombus formation in the aortic arch in a 46-year-old COVID patients in the ICU. Three trials are underway to find which anticoagulant strategy is best to treat moderate and critically ill patients where COVID-causes venous thrombo-embolism (VTE) is a major cause of complications. Image courtesy of Margarita Revzin et al.

Thrombus formation in the aortic arch in a 46-year-old COVID patients in the ICU. Three trials are underway to find which anticoagulant strategy is best to treat moderate and critically ill patients where COVID-causes venous thrombo-embolism (VTE) is a major cause of complications. Image courtesy of Margarita Revzin et al. 

Feature | Coronavirus (COVID-19) | December 23, 2020
December 23, 2020 — Three clinical trial platforms working together to test the effects of full doses of anticoagulants...
Abre venous self-expanding stent found safe, effective in treating challenging deep venous lesions was approved by the FDA.
News | Venous Therapies | October 26, 2020
October 26, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the Medtronic Abre venous self-expanding...
The NIH is heading three studies looking at various blood thinners and anticoagulants to treat COVID-19 patients with VTE.
News | Coronavirus (COVID-19) | September 11, 2020
September 11, 2020 — The National Institutes of Health (NIH) has launched two of three adaptive clinical trials...
IVC filter guidelines. The Society of Interventional Radiology (SIR) published new inferior vena cava (IVC) filter guidelines.
News | Inferior Vena Cava Filters | September 09, 2020
September 9, 2020 — The Society of Interventional Radiology (SIR) published new clinical practice guidelines that...
Rotarex S rotational atherectomy system

The Rotarex S rotational atherectomy system.

News | Atherectomy Devices | July 20, 2020
July 20, 2020 – BD (Becton, Dickinson and Company) recently completed the acquisition of Straub Medical AG, a privately...
Bilateral pulmonary embolisms seen on spectral CT. Photo courtesy of Siemens Healthineers.

Bilateral pulmonary embolisms seen on spectral CT. Photo courtesy of Siemens Healthineers.

Feature | Coronavirus (COVID-19) | May 04, 2020
May 4, 2020 — A committee comprised of vascular surgeons, medical physicians and technologists from the University of...
The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

Feature | Antiplatelet and Anticoagulation Therapies | December 27, 2019
December 27, 2019 — The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of...